NCT06441968View on ClinicalTrials.gov

Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2025

Conditions
COVID-19
Interventions
BIOLOGICAL

MPV/S-2P

A live murine pneumonia virus (MPV) vector expressing an additional SARS-CoV-2 S-protein, stabilized in its prefusion form, is being tested for its efficacy in protecting against the SARS-CoV-2 virus. It is speculated to be a next-generation vaccine for COVID-19.

Trial Locations (3)

11501

NYU Grossman Long Island School of Medicine - Vaccine Center, Mineola

30030-1705

The Hope Clinic of Emory University, Decatur

77030-3411

Baylor College of Medicine, Houston

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT06441968 - Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults | Biotech Hunter | Biotech Hunter